Cargando…

Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients

Background: SPOCK2 is a member of the SPOCK family, a 424-amino acid protein that binds to glycosaminoglycans to form proteoglycans. The purpose of this study was to explore expression profile of SPOCK2, and evaluate prognostic potential and its correlation with immune infiltration in high-grade ser...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiao, Mi, Sun, Wenbo, Li, Lina, Li, Chunyan, Zhou, Jing, Li, Qian, Duan, Lian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554533/
https://www.ncbi.nlm.nih.gov/pubmed/36246613
http://dx.doi.org/10.3389/fgene.2022.878123
_version_ 1784806719291916288
author Jiao, Mi
Sun, Wenbo
Li, Lina
Li, Chunyan
Zhou, Jing
Li, Qian
Duan, Lian
author_facet Jiao, Mi
Sun, Wenbo
Li, Lina
Li, Chunyan
Zhou, Jing
Li, Qian
Duan, Lian
author_sort Jiao, Mi
collection PubMed
description Background: SPOCK2 is a member of the SPOCK family, a 424-amino acid protein that binds to glycosaminoglycans to form proteoglycans. The purpose of this study was to explore expression profile of SPOCK2, and evaluate prognostic potential and its correlation with immune infiltration in high-grade serous ovarian cancer (HGSOC). Methods: Expression of SPOCK2 mRNA and protein between normal and tumor tissues were analyzed using the Cancer Genome Atlas database (TCGA), Gene Expression Omnibus (GEO), Clinical Proteomic Tumor Analysis Consortium (CPTAC), and the Human Protein Atlas (HPA) databases. Receiver operating characteristic (ROC) curve was used to evaluate diagnostic performance of SPOCK2. Kaplan-Meier method and Cox regression analysis were conducted to assess the effect of SPOCK2 on survival. Nomogram was used to predict the impact of SPOCK2 on prognosis. LinkedOmics were used to find correlated genes and perform functional enrichment analyses. The relationships between SPOCK2 and tumor infiltrating lymphocytes (TILs) were determined by tumor-immune system interaction database (TISIDB) and GSVA package (V1.34.0). Results: SPOCK2 was highly expressed in HGSOC tissue compared to normal tissue at both mRNA (p < 0.001) and protein (p = 0.03) levels. The area under the curve (AUC) is 0.894 (CI: 0.865–0.923). Kaplan-Meier analysis showed that HGSOC patients with high-level SPOCK2 mRNA expression had a worse overall survival (OS) than those with a low expression (HR = 1.45, p = 0.005). Univariate logistic regression analysis found that age, primary therapy outcome, tumor status, tumor residual, and SPOCK2 expression level were significantly associated with OS (p < 0.05). The nomogram model indicated an effective predictive performance of SPOCK2. Kyoto encyclopedia of genes and genomes (KEGG) and gene ontology (GO) term analyses showed that SPOCK2 were mainly involved in regulating extracellular matrix. Immune infiltration analysis showed that SPOCK2 may correlate with abundance of TILs. Conclusion: SPOCK2 has potentials to estimate diagnosis and prognosis for HGSOC and is involved in regulating extracellular matrix and immune cell infiltration.
format Online
Article
Text
id pubmed-9554533
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95545332022-10-13 Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients Jiao, Mi Sun, Wenbo Li, Lina Li, Chunyan Zhou, Jing Li, Qian Duan, Lian Front Genet Genetics Background: SPOCK2 is a member of the SPOCK family, a 424-amino acid protein that binds to glycosaminoglycans to form proteoglycans. The purpose of this study was to explore expression profile of SPOCK2, and evaluate prognostic potential and its correlation with immune infiltration in high-grade serous ovarian cancer (HGSOC). Methods: Expression of SPOCK2 mRNA and protein between normal and tumor tissues were analyzed using the Cancer Genome Atlas database (TCGA), Gene Expression Omnibus (GEO), Clinical Proteomic Tumor Analysis Consortium (CPTAC), and the Human Protein Atlas (HPA) databases. Receiver operating characteristic (ROC) curve was used to evaluate diagnostic performance of SPOCK2. Kaplan-Meier method and Cox regression analysis were conducted to assess the effect of SPOCK2 on survival. Nomogram was used to predict the impact of SPOCK2 on prognosis. LinkedOmics were used to find correlated genes and perform functional enrichment analyses. The relationships between SPOCK2 and tumor infiltrating lymphocytes (TILs) were determined by tumor-immune system interaction database (TISIDB) and GSVA package (V1.34.0). Results: SPOCK2 was highly expressed in HGSOC tissue compared to normal tissue at both mRNA (p < 0.001) and protein (p = 0.03) levels. The area under the curve (AUC) is 0.894 (CI: 0.865–0.923). Kaplan-Meier analysis showed that HGSOC patients with high-level SPOCK2 mRNA expression had a worse overall survival (OS) than those with a low expression (HR = 1.45, p = 0.005). Univariate logistic regression analysis found that age, primary therapy outcome, tumor status, tumor residual, and SPOCK2 expression level were significantly associated with OS (p < 0.05). The nomogram model indicated an effective predictive performance of SPOCK2. Kyoto encyclopedia of genes and genomes (KEGG) and gene ontology (GO) term analyses showed that SPOCK2 were mainly involved in regulating extracellular matrix. Immune infiltration analysis showed that SPOCK2 may correlate with abundance of TILs. Conclusion: SPOCK2 has potentials to estimate diagnosis and prognosis for HGSOC and is involved in regulating extracellular matrix and immune cell infiltration. Frontiers Media S.A. 2022-09-28 /pmc/articles/PMC9554533/ /pubmed/36246613 http://dx.doi.org/10.3389/fgene.2022.878123 Text en Copyright © 2022 Jiao, Sun, Li, Li, Zhou, Li and Duan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Jiao, Mi
Sun, Wenbo
Li, Lina
Li, Chunyan
Zhou, Jing
Li, Qian
Duan, Lian
Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients
title Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients
title_full Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients
title_fullStr Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients
title_full_unstemmed Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients
title_short Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients
title_sort clinical significance of spock2 expression signature for high-grade serous ovarian cancer patients
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554533/
https://www.ncbi.nlm.nih.gov/pubmed/36246613
http://dx.doi.org/10.3389/fgene.2022.878123
work_keys_str_mv AT jiaomi clinicalsignificanceofspock2expressionsignatureforhighgradeserousovariancancerpatients
AT sunwenbo clinicalsignificanceofspock2expressionsignatureforhighgradeserousovariancancerpatients
AT lilina clinicalsignificanceofspock2expressionsignatureforhighgradeserousovariancancerpatients
AT lichunyan clinicalsignificanceofspock2expressionsignatureforhighgradeserousovariancancerpatients
AT zhoujing clinicalsignificanceofspock2expressionsignatureforhighgradeserousovariancancerpatients
AT liqian clinicalsignificanceofspock2expressionsignatureforhighgradeserousovariancancerpatients
AT duanlian clinicalsignificanceofspock2expressionsignatureforhighgradeserousovariancancerpatients